American Oriental Bioengineering, Inc. completed two acquisitions while, at the same time, announcing it had declined to pursue a third. In August, AOB had announced a signed letter of intent to pay $110 million to acquire an unnamed China pharmaceutical distributor with $550 million in annual revenues. That deal has been scotched, and two smaller acquisitions, one for a drug distributor and the other for a drug developer, have been completed in its place for a smaller total outlay of $53.1 million. More details...
Stock Symbol: (NYSE: AOB)